FAAH Inhibitors
Drugs that block anandamide breakdown, not terpenes or cannabinoids.
FAAH inhibitors are pharmacologically sound—they reliably raise anandamide in humans. But they are not terpenes, not present in cannabis flower, and not approved for any medical use despite 20+ years of research. The clinical promise has not materialized. The BIA 10-2474 disaster in 2016 also cooled industry interest. Understanding FAAH is useful for endocannabinoid biology; marketing claims linking them to cannabis terpenes are not.
What FAAH inhibitors are—and what they are not
FAAH inhibitors are synthetic drugs, not terpenes or cannabinoids. They do not occur naturally in cannabis flower in any meaningful amount, and they have no aroma profile or boiling point relevant to cannabis consumption. This article explains what they are and why they matter for understanding the endocannabinoid system.
Fatty acid amide hydrolase (FAAH) is a membrane-bound enzyme that breaks down fatty acid amides—most importantly anandamide (N-arachidonoylethanolamine, AEA), one of the two principal endocannabinoids [1] Strong evidence. When FAAH is inhibited, anandamide accumulates in tissues and signals more strongly at CB1 and CB2 receptors. This is mechanistically distinct from THC, which directly activates CB1. The theoretical appeal is that FAAH inhibitors boost endogenous endocannabinoid signaling only where and when anandamide is already being released—producing, in animal models, analgesia and anxiolysis with potentially less intoxication and tolerance than direct CB1 agonists [3] Weak / limited.
How FAAH inhibitors work in the body
When FAAH is active, it terminates anandamide signaling by hydrolyzing (breaking down) the molecule. Blocking FAAH keeps anandamide concentrations elevated, prolonging and enhancing CB1 and CB2 activation [2] Strong evidence.
In rodents, FAAH inhibitors reliably reduce anxiety and pain behaviors [3] Strong evidence. However, translating this to humans has proven difficult. The challenge is that raising anandamide in humans does not yet produce the clinical benefits that animal models predicted, a frustration common across endocannabinoid drug development Weak / limited.
Representative compounds and clinical trials
Several FAAH inhibitors have entered human testing:
- URB597 (KDS-4103): A carbamate-based irreversible inhibitor widely used as a research tool. Robust anxiolytic and analgesic effects in rodent models [3] Strong evidence; never advanced to clinical approval.
- PF-04457845 (Pfizer): An orally bioavailable selective FAAH inhibitor. A randomized controlled trial found modest reductions in cannabis withdrawal symptoms and cannabis use over four weeks [4] Weak / limited. A separate trial in osteoarthritis pain failed to beat placebo [7] Strong evidence.
- JNJ-42165279 (Janssen): Tested in social anxiety disorder and major depressive disorder with mixed-to-disappointing results Weak / limited.
- BIA 10-2474 (Bial): Caused one death and severe neurological injury to four other volunteers in a Phase 1 trial in Rennes, France in January 2016 [5] Strong evidence. Subsequent analysis revealed that off-target lipase inhibition, not FAAH inhibition itself, was responsible for the toxicity [6] Strong evidence. The incident highlighted the risks of broader enzyme inhibition and significantly reduced industry enthusiasm for the class.
Bottom line: Despite roughly two decades of development, no FAAH inhibitor is approved for any medical indication anywhere Strong evidence. Raising anandamide has not yet translated into clear clinical benefit at the doses and durations tested.
FAAH inhibitors and cannabis: what you should know
Several claims link FAAH inhibitors to cannabis use; here is what the evidence shows:
CBD and FAAH inhibition: Early in vitro research suggested cannabidiol (CBD) weakly inhibits FAAH, but the effect is species-specific and much weaker in human FAAH than in rat FAAH [8] Disputed. The widespread claim that 'CBD works by raising anandamide via FAAH inhibition' is unsupported by strong evidence in humans.
Terpenes as FAAH inhibitors: Popular claims that specific terpenes like myrcene, limonene, or beta-caryophyllene 'inhibit FAAH and boost your high' lack supporting evidence at physiologically relevant concentrations No data. No terpene found in cannabis flower inhibits FAAH at concentrations that would meaningfully accumulate during smoking or vaping.
Genetic variation in FAAH: A common human variant (C385A, rs324420) reduces FAAH activity and is associated with higher circulating anandamide. This variant has been linked, inconsistently, to differences in anxiety, pain sensitivity, and cannabis use patterns [9] Weak / limited—a reminder that endocannabinoid biology is individual, not determined by strain name or terpene profile.
Why clinical trials have disappointed
FAAH inhibitors represent a pharmacologically sound approach: they target the endocannabinoid system at a specific, well-characterized step. Animal models consistently show anxiolytic and analgesic effects. Yet human trials have yielded few compelling results.
Possible explanations include:
- Anandamide is not the limiting step. Raising one endocannabinoid may not be sufficient if the therapeutic problem lies elsewhere in the signaling cascade or in other brain systems Weak / limited.
- Tolerance and compensatory feedback. Chronic elevation of anandamide may trigger downregulation of CB1 receptors or other adaptive responses Weak / limited.
- Study design limitations. Some trials were small or short-duration; others may have enrolled heterogeneous populations in which FAAH inhibition helps a subgroup but not the overall population Weak / limited.
This pattern—robust preclinical efficacy followed by clinical disappointment—is not unique to FAAH inhibitors; it reflects the broader difficulty in translating endocannabinoid biology into medicine Weak / limited.
Is FAAH a target for cannabis research?
FAAH remains a legitimate research target in academic endocannabinoid biology. Understanding how the body breaks down anandamide helps clarify endocannabinoid signaling, which is relevant to pain, anxiety, memory, and immune function.
However, for cannabis users, FAAH inhibitors are not a practical consideration. They are not sold over the counter, not present in cannabis flower or derivatives, and not approved for clinical use. The connection to cannabis is indirect: FAAH inhibitors and cannabinoids both affect the endocannabinoid system, but they do so through different mechanisms (indirect vs. direct CB1/CB2 activation) and with very different risk–benefit profiles Weak / limited.
Claims that cannabis strains or terpene profiles 'activate FAAH inhibition' or 'mimic FAAH inhibitor effects' are marketing folklore, not pharmacology No data.
Sources
- Peer-reviewed Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384(6604):83–87.
- Peer-reviewed McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem. 2005;74:411–432.
- Peer-reviewed Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003;9(1):76–81.
- Peer-reviewed D'Souza DC, Cortes-Briones J, Creatura G, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 2019;6(1):35–45.
- Peer-reviewed Kerbrat A, Ferré JC, Fillatre P, et al. Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. N Engl J Med. 2016;375(18):1717–1725.
- Peer-reviewed van Esbroeck ACM, Janssen APA, Cognetta AB, et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science. 2017;356(6342):1084–1087.
- Peer-reviewed Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain. 2012;153(9):1837–1846.
- Peer-reviewed Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134(4):845–852.
- Peer-reviewed Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA. 2002;99(12):8394–8399.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- FAAH Enzyme — The enzyme that degrades your body's endogenous cannabinoids, and why blocking it has larg...
- HHC (Hexahydrocannabinol) — A semi-synthetic cannabinoid with minimal human safety data and uncertain legal status.
- OEA (Oleoylethanolamide) — An endogenous lipid amide that is not produced by cannabis but often misidentified as one.
- THC:CBD Ratios and Effects — How the balance between THC and CBD in a cannabis product shapes its psychoactivity, side...